PET study of the pre- and post-synaptic dopaminergic markers for the neurodegenerative process in Huntington's disease

Brain

Volumn 120, Issue 3, 1997, Pages 503-514

  Ginovart, Nathalie ^a,d   Lundin, Anders ^a   Farde, Lars ^a   Halldin, Christer ^a   Bäckman, Lars ^a,b,c   Swahn, Carl Gunnar ^a   Pauli, Stefan ^a   Sedvall, Göran ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b Gerontology Research Center   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Dopamine receptors; Dopamine transporter; Huntington's disease; MRI; PET

Indexed keywords

DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER;

ADULT; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; NERVE CELL; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SYNAPTOSOME;

(R)-2,3,4,5-TETRAHYDRO-8-CHLORO-3-METHYL-5-PHENYL-1H-3-BENZAZEPIN-7-OL; ADULT; BRAIN; CARBON RADIOISOTOPES; COCAINE; DOPAMINE ANTAGONISTS; FEMALE; HUMANS; HUNTINGTON DISEASE; IODINE RADIOISOTOPES; LIGANDS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEURONS; RACLOPRIDE; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, PRESYNAPTIC; SALICYLAMIDES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030897476     PISSN: 00068950     EISSN: None     Source Type: Journal    
DOI: 10.1093/brain/120.3.503     Document Type: Article

References (64)

1. Agid Y. Approche pharmacologique de la chorée de Huntington. Rev Neurol (Paris) 1975; 131: 847-65.
2. Bergström M, Boëthius J, Eriksson L, Greitz T, Ribbe T, Widén L. Head fixation device for reproducible position alignment in transmission CT and positron emission tomography. J Comput Assist Tomogr 1981; 5: 136-41.
3. Bergström M, Litton J, Eriksson L, Bohm C, Blomqvist G. Determination of object contour from projections for attenuation correction in cranial positron emission tomography. J Comput Assist Tomogr 1982; 6: 365-72.
4. Bird ED, Iversen LL. Huntington's chorea. Post-mortem measurement of glutamic acid decarboxylase, choline acetyltransferase and dopamine in basal ganglia. Brain 1974; 97: 457-72.
5. Brandt J, Folstein SE, Wong DF, Links J, Dannals RF, McDonnell-Sill A, et al. D2 receptors in Huntington's disease: positron emission tomography findings and clinical correlates. J Neuropsychiatry Clin Neurosci 1990; 2: 20-7.
6. Brownell AL, Hantraye P, Wullner U, Hamberg L, Shoup T, Elmaleh DR, et al. PET- and MRI-based assessment of glucose utilization, dopamine receptor binding, and hemodynamic changes after lesions to the caudate-putamen in primates. Exp Neurol 1994; 125: 41-51.
7. 3H]mazindol. Neuroscience 1992; 49: 317-27.
8. Cortés R, Camps M, Gueye B, Probst A, Palacios JM. Dopamine receptors in human brain: autoradiographic distribution of D1 and D2 sites in Parkinson syndrome of different etiology. Brain Res 1989; 483: 30-8.
9. Cross A, Rossor M. Dopamine D-1 and D-2 receptors in Huntington's disease. Eur J Pharmacol 1983; 88: 223-9.
10. Cunha L, Oliveira CR, Diniz M, Amaral R, Concalves AF, Pio-Abreu J. Homovanilic acid in Huntington's disease and Sydenham's chorea. J Neurol Neurosurg Psychiatry 1981; 44: 258-61.
11. De la Monte SM, Vonsattel JP, Richardson EP Jr. Morphometric demonstration of atrophic changes in the cerebral cortex, white matter, and neostriatum in Huntington's disease. J Neuropathol Exp Neurol 1988; 47: 516-25.
12. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET. Science 1986; 231: 258-61.
13. 11C-raclopride. Psychopharmacology (Berl) 1987; 92: 278-84.
14. Farde L, Nordström AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Arch Gen Psychiatry 1992; 49: 538-44.
15. 11C]β-CIT binding to monoamine transporters in the monkey and human brain. Synapse 1994; 16: 93-103.
16. 11C]raclopride in man. Synapse 1995; 20: 200-8.
17. Ferrante RJ, Kowall NW. Tyrosine hydroxylase-like immunoreactivity is distributed in the matrix compartment of normal human and Huntington's disease striatum. Brain Res 1987; 416: 141-6.
18. 3H]SCH 23390. Brain Res 1987a; 408: 205-9.
19. 3H]sulpiride. Eur J Pharmacol 1987b; 138: 61-8.
20. 3H]SCH 23390 and correlation with [3H]forskolin binding. Exp Neurol 1990; 110: 219-27.
21. Folstein SE. Huntington's disease: a disorder of families. Baltimore: Johns Hopkins University Press, 1989.
22. Folstein MF, Folstein SE, McHugh pR. 'Mini-mental state': a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
23. Folstein SE, Jensen B, Leigh RJ, Folstein MF. The measurement of abnormal movement: Methods developed for Huntington's disease. Neurobehav Toxicol Teratol 1983; 5: 605-9.
24. Garrett MC, Soares-da-Silva P. Increased cerebrospinal fluid dopamine and 3,4-dihydroxyphenylacetic acid levels in Huntington's disease: evidence for an overactive dopaminergic brain transmission. J Neurochem 1992; 58: 101-6.
25. Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996; 379: 606-12.
26. Goto S, Hirano A, Rojas-Corona RR. An immunohistochemical investigation of the human neostriatum in Huntington's disease. Ann Neurol 1989; 25: 298-304.
27. 11C-N-methyl-spiperone. Acta Neurol Scand 1987; 75: 87-94.
28. Haglund MM, Ojemann GA, Schwartz TW, Lettich E. Neuronal activity in human lateral temporal cortex during serial retrieval from short-term memory. J Neurosci 1994; 14: 1507-15.
29. 3H-raclopride. J Neural Transm 1988; 73: 7-21.
30. 11C]labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum [A] 1986; 37: 1039-43.
31. Halldin C, Farde L, Högberg T, Hall H, Ström P, Ohlberger A, et al. A comparative PET-study of five carbon-11 or fluorine-18 labelled salicylamides. Preparation and in vitro dopamine D-2 receptor binding. Nucl Med Biol 1991; 18: 871-81.
32. Halldin C, Swahn CG, Farde L, Sedvall G. Radioligand disposition and metabolism. Key information in early drug development. In: Comar D, editor. PET for drug development and evaluation. Dordrecht: Kluwer Academic, 1995: 55-65.
33. 11C]β-CIT-FE, a radioligand for quantitation of the dopamine transporter in the living brain using positron emission tomography. Synapse 1996; 22: 386-90.
34. Harris GJ, Pearlson GD, Peyser CE, Aylward EH, Roberts J, Barta PE, et al. Putamen volume reduction on magnetic resonance imaging exceeds caudate changes in mild Huntington's disease. Ann Neurol 1992; 31: 69-75.
35. Hasselbalch SG, Oberg G, Sorensen SA, Andersen AR, Waldemar G, Schmidt JF, et al. Reduced regional cerebral blood flow in Huntington's disease studied by SPECT. J Neurol Neurosurg Psychiatry 1992; 55: 1018-23.
36. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes [see comments]. Cell 1993; 72: 971-83. Comment in cell 1993; 72: 817-8.
37. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes [see comments]. Cell 1993; 72: 971-83. Comment in cell 1993; 72: 817-8.
38. Jernigan TL, Salmon DP, Butters N, Hesselink JR. Cerebral structure on MRI. II: Specific changes in Alzheimer's and Huntington's disease. Biol Psychiatry 1991; 29: 68-81.
39. Joyce JN, Marshall JF. Quantitative autoradiography of dopamine D2 sites in rat caudate-putamen: localization to intrinsic neurons and not to neocortical afferents. Neuroscience 1987; 20: 773-95.
40. Joyce JN, Lexow N, Bird E, Winokur A. Organization of dopamine D1 and D2 receptors in human striatum: receptor autoradiographic studies in Huntington's disease and Schizophrenia. Synapse 1988; 2: 546-57.
41. Kish SJ, Shannak K, Hornykiewicz O. Elevated serotonin and reduced dopamine in subregionally divided Huntington's disease striatum. Ann Neurol 1987; 22: 386-9.
42. Lange H, Thörner G, Hopf A, Schröder KF. Morphometric studies of the neuropathological changes in choreatic diseases. J Neurol Sci 1976; 28: 401-25.
43. 123I]b-CIT: pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13: 295-309.
44. 123I]β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14: 982-94.
45. Leenders KL, Frackowiak RS, Quinn N, Marsden CD. Brain energy metabolism and dopaminergic function in Huntington's disease measured in vivo using positron emission tomography. Mov Dis 1986; 1: 69-77.
46. Litton J, Bergström M, Eriksson L, Bohm C, Blomqvist G, Kesselberg M. Performance study of the PC-384 positron camera system for emission tomography of the brain. J Comput Assist Tomogr 1984; 8: 74-87.
47. Lueschow A, Miller EK, Desimone R. Inferior temporal mechanisms for invariant object recognition. Cereb Cortex 1994; 5: 523-31.
48. 11C]β-CIT-FP, a potential radioligand for quantitation of the dopamine transporter: preparation, autoradiography, metabolite studies, and positron emission tomography examinations. Nucl Med Biol 1995; 22: 905-13.
49. 11C]β-CIT, a cocaine analogue. Preparation, autoradiography and preliminary PET investigations. Nucl Med Biol 1993; 20: 249-55.
50. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3: 1-7.
51. Reisine TD, Fields JZ, Stern LZ, Johnson PC, Bird ED, Yamamura HI. Alterations in dopaminergic receptors in Huntington's disease. Life Sci 1977; 21: 1123-8.
52. Richfield EK, O'Brien CF, Eskin T, Shoulson I. Heterogeneous dopamine receptor changes in early and late Huntington's disease. Neurosci Lett 1991; 132: 121-6.
53. Sawaguchi T, Goldman-Rakic PS. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 1991; 251: 947-50.
54. Sax DS, O'Donnell B, Butters N, Menzer L, Montgomery K, Kayne HL. Computed tomographic, neurologic, and neuropsychological correlates of Huntington's disease. Int J Neurosci 1983; 18: 21-36.
55. Sedvall G, Farde L, Stone-Elander S, Halldin C. Dopamine D1-receptor binding in the living human brain. In: Breese GR, Creese I, editors. Neurobiology of central D1-dopamine receptors. New York: Plenum Press, 1986: 119-24.
56. Sedvall G, Karlsson P, Lundin A, Anvret M, Suhara T, Halldin C, et al. Dopamine D1 receptor number - a sensitive PET marker for early brain degeneration in Huntington's disease. Eur Arch Psychiatry Clin Neurosci 1994; 243: 249-55.
57. Shaya EK, Scheffel U, Dannals RF, Ricaurte GA, Carroll FI, Wagner HN Jr, et al. In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55. Synapse 1992; 10: 169-72.
58. Spokes EGS. Neurochemical alterations in Huntington's chorea. A study of post-mortem brain tissue. Brain 1980; 103: 179-210.
59. 11C]SCH 23390. Identification of two radiolabelled metabolites with HPLC. Human Psychopharmacol 1994; 9: 25-31.
60. Turjanski N, Weeks R, Dolan R, Harding AE, Brooks DJ. Striatal D1 and D2 receptor binding in patients with Huntington's disease and other choreas. A PET study. Brain 1995; 118: 689-96.
61. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-77.
62. Waters CM, Peck R, Rossor M, Reynolds GP, Hunt SP. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea. Neuroscience 1988; 25: 419-38.
63. Wienhard K, Dahlbom M, Eriksson L, Michel C, Bruckbauer T, Pietrzyk U, et al. The ECAT EXACT HR: performance of a new high resolution positron scanner. J Comput Assist Tomogr 1994; 18: 110-8.
64. Wong DF, Links JM, Wagner HN, Folstein SE, Suneja S, Dannals RF, et al. Dopamine and serotonin receptors measured in vivo in Huntington's disease with C-11 N-methylspiperone PET imaging [abstract]. J Nucl Med 1985; 26 Suppl: P107.